Jazz Pharmaceuticals has acquired Actio Biosciences, Inc. for $1.3 billion in an all-cash transaction. The deal, which has been approved by the boards of both companies, is expected to close in the second half of this year. Actio Biosciences will operate as a wholly owned subsidiary of Jazz Pharmaceuticals following the completion of the acquisition.
Actio Biosciences focuses on leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases. The company’s approach combines expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized, with the goal of streamlining drug development and bringing forward potent, precisely targeted therapeutics for patients.
For Jazz Pharmaceuticals, the acquisition adds a pipeline of precision medicine candidates that complement its existing portfolio in neuroscience and oncology. Actio’s platform, which aims to translate genetic insights into therapies applicable across multiple patient populations, is expected to broaden Jazz’s research capabilities. The deal provides Jazz with access to early-stage programs that could address conditions with high unmet need, while leveraging Actio’s data-driven approach to reduce development uncertainty.
The transaction is structured to deliver immediate value to Jazz by expanding its pipeline without disrupting its current commercial operations. Actio’s team is expected to remain in place, integrating into Jazz’s research and development organization. Jazz has stated that the acquisition will be funded through existing cash reserves and debt financing, and it does not anticipate any material impact on its near-term earnings guidance.
With the integration underway, the combined entity will focus on advancing Actio’s lead programs through clinical development while continuing to explore additional indications. Jazz’s established global infrastructure is expected to support the progression of these assets, though specific development timelines have not yet been disclosed. The success of the acquisition will depend on the execution of Actio’s pipeline and the ability to translate its genetic insights into approved therapies.